Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1190B in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT06822868Phase 1Recruiting
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-1190B in B-cell non-Hodgkin lymphoma. Primary endpoints: Adverse Events (AE) after CT1190B infusion at 12 months and Maximum Tolerated Dose and/or dose range at 28 days. Started Feb 2025; status: recruiting.
02
Drugs
CT-1190B
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06822868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822868.